4//SEC Filing
Magnani John L. 4
Accession 0001209191-22-004893
CIK 0001253689other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 9:01 PM ET
Size
8.1 KB
Accession
0001209191-22-004893
Insider Transaction Report
Form 4
Magnani John L.
DirectorVP of Research, CSO
Transactions
- Award
Employee Stock Option (right to buy)
2022-01-21+100,000→ 100,000 totalExercise: $1.11Exp: 2032-01-20→ Common Stock (100,000 underlying) - Award
Employee Stock Option (right to buy)
2022-01-21+25,000→ 25,000 totalExercise: $1.11Exp: 2032-01-20→ Common Stock (25,000 underlying)
Footnotes (2)
- [F1]25% of the shares underlying this option will vest on January 21, 2023 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
- [F2]50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.
Documents
Issuer
GLYCOMIMETICS INC
CIK 0001253689
Entity typeother
Related Parties
1- filerCIK 0001589713
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 9:01 PM ET
- Size
- 8.1 KB